| Literature DB >> 34566419 |
Mohammed Elshafie1, Azza Srour2, Hussien El-Ansarey2, Mostafa Abdel-Kader2, Ibrahim Kabbash3, Mohamed Mashaly4.
Abstract
AIM: The FDA approved isotretinoin for moderate and severe nodulo-cystic acne, in which it proved effective. However, this misled the dermatologists into using isotretinoin for mild cases as well. This misuse increased the risk of developing adverse effects, especially on the ocular system. These adverse effects vary from mild reversible eye dryness to severe irreversible loss of night vision. Also, it causes contact lens intolerance and corneal ulcer on top. Both ophthalmologists and dermatologists have different perceptions of the drug.Entities:
Keywords: academic; awareness; ocular dryness; ophthalmic adverse effects
Year: 2021 PMID: 34566419 PMCID: PMC8457441 DOI: 10.2147/CCID.S327870
Source DB: PubMed Journal: Clin Cosmet Investig Dermatol ISSN: 1178-7015
Gender and Academic Degrees of Participants
| Variables | Frequency | Percentage |
|---|---|---|
| Females | 96 | 86.5 |
| Males | 15 | 13.5 |
| Master | 47 | 42.3 |
| Diploma | 23 | 20.7 |
| MD | 22 | 19.8 |
| PhD | 9 | 8.1 |
| Bachelor | 7 | 6.3 |
| Board | 3 | 2.7 |
Figure 1The percent (%) of the participants from different Egyptian governorate; indicating Dakahlia as the highest representation.
Figure 2The percent (%) of the institutions of the participants; indication that most of them are from general hospitals.
Ocular Side Effects Knowledge, Informing the Patients About Ocular Effects, Recent Refractive Surgery Screening and Warning of Refractive Surgeries for Six Months After Drug Stoppage
| Variables | Frequency | Percentage |
|---|---|---|
| Yes | 105 | 94.6 |
| No | 6 | 5.4 |
| Yes | 100 | 90.1 |
| Sometimes | 8 | 7.2 |
| No | 3 | 2.7 |
| Yes | 83 | 74.8 |
| No | 28 | 25.2 |
| Always | 41 | 36.9 |
| Sometimes | 49 | 44.1 |
| Rarely | 21 | 18.9 |
| Yes | 43 | 38.7 |
| Sometimes | 34 | 30.6 |
| No | 34 | 30.6 |
| Always | 4 | 3.6 |
| Sometimes | 63 | 58.8 |
| Rarely | 44 | 39.6 |
| Always | 52 | 46.8 |
| Sometimes | 31 | 27.9 |
| Rarely | 28 | 25.2 |
Relationship Between Dermatologists’ Academic Degree and Their Knowledge and Performance About Isotretinoin Therapy
| Variables | Academic Degree | P value | |||||
|---|---|---|---|---|---|---|---|
| Bachelor/Board (n=10) | Diploma/M.Sc. (n=70) | MD/PhD (n=31) | |||||
| n | % | n | % | n | % | ||
| 0.636 | |||||||
| Always | 0 | 0.0 | 3 | 4.3 | 0 | 0.0 | |
| Sometimes | 10 | 100.0 | 64 | 91.4 | 29 | 93.5 | |
| Rarely | 0 | 0.0 | 3 | 4.3 | 2 | 6.5 | |
| 0.099 | |||||||
| Yes | 8 | 80.0 | 67 | 95.7 | 30 | 69.8 | |
| No | 2 | 20.0 | 3 | 4.3 | 1 | 3.2 | |
| 0.350 | |||||||
| Always | 1 | 10.0 | 26 | 37.2 | 14 | 45.2 | |
| Sometimes | 6 | 60.0 | 32 | 45.7 | 11 | 35.5 | |
| Rarely | 3 | 30.0 | 12 | 17.1 | 6 | 19.3 | |
| 0.039* | |||||||
| Yes | 1 | 10.0 | 32 | 45.7 | 10 | 32.2 | |
| Sometimes | 2 | 20.0 | 20 | 28.6 | 12 | 38.7 | |
| No | 7 | 70.0 | 18 | 25.7 | 9 | 29.1 | |
| 0.421 | |||||||
| Yes | 6 | 60.0 | 52 | 74.3 | 25 | 80.7 | |
| No | 4 | 40.0 | 18 | 25.7 | 6 | 19.3 | |
| 0.003* | |||||||
| Yes | 8 | 80.0 | 66 | 94.3 | 26 | 83.9 | |
| Sometimes | 0 | 0.0 | 4 | 5.7 | 4 | 12.9 | |
| No | 2 | 20.0 | 0 | 0.0 | 1 | 3.2 | |
| 0.767 | |||||||
| Always | 0 | 0.0 | 2 | 2.9 | 2 | 6.4 | |
| Sometimes | 5 | 50.0 | 40 | 57.1 | 18 | 58.1 | |
| Rarely | 5 | 50.0 | 28 | 40.0 | 11 | 35.5 | |
| 0.721 | |||||||
| Always | 3 | 30.0 | 32 | 45.7 | 17 | 54.8 | |
| Sometimes | 4 | 40.0 | 20 | 28.6 | 7 | 22.6 | |
| Rarely | 3 | 30.0 | 18 | 25.7 | 7 | 22.6 | |
Note: *Significant.
Relationship Between Dermatologists’ Years of Experience and Their Knowledge and Performance About Isotretinoin Therapy
| Variables | Years of Experience | P value | |||||
|---|---|---|---|---|---|---|---|
| 0–10 (n=85) | 11–20 (n=19) | 21–30 (n=7) | |||||
| n | % | n | % | n | % | ||
| 0.858 | |||||||
| Always | 3 | 3.5 | 0 | 0.0 | 0 | 0.0 | |
| Sometimes | 78 | 91.8 | 18 | 94.7 | 7 | 100.0 | |
| Rarely | 4 | 4.7 | 1 | 5.3 | 0 | 0.0 | |
| 0.803 | |||||||
| Yes | 80 | 94.1 | 18 | 94.7 | 7 | 100.0 | |
| No | 5 | 5.9 | 1 | 5.3 | 0 | 0.0 | |
| 0.591 | |||||||
| Always | 29 | 34.1 | 8 | 42.1 | 4 | 57.1 | |
| Sometimes | 39 | 45.9 | 7 | 36.8 | 3 | 42.9 | |
| Rarely | 17 | 20.0 | 4 | 21.1 | 0 | 0.0 | |
| 0.329 | |||||||
| Yes | 30 | 35.3 | 8 | 42.1 | 5 | 71.4 | |
| Sometimes | 29 | 34.1 | 4 | 21.1 | 1 | 14.3 | |
| No | 26 | 30.6 | 7 | 36.8 | 1 | 14.3 | |
| 0.012* | |||||||
| Yes | 58 | 68.2 | 19 | 100.0 | 6 | 85.7 | |
| No | 27 | 31.8 | 0 | 0.0 | 1 | 14.3 | |
| 0.775 | |||||||
| Yes | 78 | 91.8 | 16 | 84.2 | 6 | 85.7 | |
| Sometimes | 5 | 5.9 | 2 | 10.5 | 1 | 14.3 | |
| No | 2 | 2.3 | 1 | 5.3 | 0 | 0.0 | |
| 0.810 | |||||||
| Always | 3 | 3.5 | 1 | 5.3 | 0 | 0.0 | |
| Sometimes | 46 | 54.1 | 12 | 63.1 | 5 | 71.4 | |
| Rarely | 36 | 42.4 | 6 | 31.6 | 2 | 28.6 | |
| 0.245 | |||||||
| Always | 39 | 45.9 | 7 | 36.8 | 6 | 85.7 | |
| Sometimes | 25 | 29.4 | 6 | 31.6 | 0 | 0.0 | |
| Rarely | 21 | 24.7 | 6 | 31.6 | 1 | 14.3 | |
Note: *Significant.